Safety and efficacy of IDegLira titrated once weekly versus twice weekly in patients with type 2 diabetes uncontrolled on oral antidiabetic drugs: DUAL VI randomized clinical trial
Zepbound (tirzepatide) - This dual-action medication targets both GLP-1 and GIP receptors, achieving remarkable results with up to 22.5% weight loss in clinical studies
The New England Journal of Medicine, 393 (11), 10771087
The standard study witnessed that the majority of patients, around 70% experience side effects
Semaglutide , a GLP-1 receptor agonist, is an effective medication for both type 2 diabetes and weight management, and our medical team will be with you every step of the way
Easy dosing: Inject GLP-1s with easy-to-use single-dose or multi-dose pens